Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights

Receptor tyrosine kinases (RTKs) inhibitors’ activity in advanced osteosarcoma is significant but short-lived. To prevent or at least delay drug resistance, we explored a vertical inhibition by combining drugs acting at different levels of the RTK pathways (pazopanib + trametinib). We studied pazopa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Chiabotto, Giulia, Grignani, Giovanni, Todorovic, Maja, Martin, Valentina, Centomo, Maria Laura, Prola, Elisa, Giordano, Giorgia, Merlini, Alessandra, Miglio, Umberto, Berrino, Enrico, Napione, Lucia, Isella, Claudio, Capozzi, Federica, Basiricò, Marco, Marsero, Cristina, Gerardi, Ilaria, Venesio, Tiziana, Sangiolo, Dario, Aglietta, Massimo, D’Ambrosio, Lorenzo, Pignochino, Ymera
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7352822/
https://ncbi.nlm.nih.gov/pubmed/32531992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061519
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados